Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for predicting therapeutic effect of chemotherapy on hepatocellular carcinoma patient

A therapeutic effect, hepatocyte technology, applied in the fields of organic chemistry, testing water, digestive system, etc., can solve the problem of no established standard therapy treatment method, no treatment method, etc., to achieve excellent therapeutic effect, prolong life effect, and reduce burden. Effect

Inactive Publication Date: 2012-10-10
TAIHO PHARMA CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] As mentioned above, in terms of the treatment system for hepatocellular carcinoma, there is no established treatment method that should be regarded as the standard therapy, and the current situation is that there is no effective treatment method, especially after TAE surgery.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for predicting therapeutic effect of chemotherapy on hepatocellular carcinoma patient
  • Method for predicting therapeutic effect of chemotherapy on hepatocellular carcinoma patient
  • Method for predicting therapeutic effect of chemotherapy on hepatocellular carcinoma patient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] (Example 1) Calculation of cutoff point

[0076] A clinical trial comparing the TSU-68 administration group and the non-administration group was carried out for patients diagnosed with hepatocellular carcinoma who were not suitable for liver resection and percutaneous local therapy and who received TACE. Here, the antineoplastic agent used in TACE is epirubicin.

[0077] Subject cases were randomly divided into TSU-68 administration group and non-administration group. For the cases classified into the TSU-68 administration group, the administration of TSU-68 was started within 2 weeks after receiving TACE. For the administration of TSU-68, 200 mg once a day was administered orally twice a day after breakfast and dinner. In the non-administration group, no further treatment for cancer was performed after receiving TACE, and a follow-up observation was performed.

[0078] The deterioration-free survival period starts from the date of receiving TACE, and is set to the e...

Embodiment 2

[0096] (Example 2) Therapeutic effect in selected patients with PDGF-BB or IL-8 as an index

[0097] Using the cutoff points calculated in Example 1, analysis of the survival period of the TSU-68-administered group and the non-administered group in the PDGF-BB or IL-8 high-expression group and low-expression group was performed. Table 3 to Table 9 show the results.

[0098] [table 3]

[0099] PDGF-BB cut-off point; 1480pg / ml

[0100] (The difference in the 6-month progression-free survival rate is the lower limit of 20% or more)

[0101]

[0102]

[0103] As shown in the above Table 3, the lower limit value of the cutoff point of 20% or more is the difference in the 6-month progression-free survival rate between the TSU-68 administration group and the non-administration group as the PDGF-BB high expression group When 1480pg / ml was used as the cutoff point, in the PDGF-BB low expression group, the TSU-68 administration group showed almost the same therapeutic effect as...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is a method for predicting the therapeutic effect of a chemotherapy on a hepatocellular carcinoma patient who underwent hepatic artery embolization, and an antitumor agent for treating a carcinoma patient on whom said chemotherapy is predicted to highly likely exert sufficient therapeutic effect. In the method for predicting the therapeutic effect of a chemotherapy on a hepatocellular carcinoma patient who underwent hepatic artery embolization, the expression amount of PDGF-BB or IL-8 is used as an indicator. The antitumor agent for treating a carcinoma patient is predicted, by the aforesaid prediction method, to highly likely exert sufficient therapeutic effect.

Description

technical field [0001] The present invention relates to a method for predicting the use of (Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene) formazan for patients with hepatocellular carcinoma undergoing hepatic artery embolization. Base] 2,4-dimethyl-1H-pyrrole-3-propionic acid (hereinafter referred to as "TSU-68") or a method for the therapeutic effect of chemotherapy of an antitumor agent of a salt thereof and a method for predicting An antitumor agent for treating cancer patients with a high possibility of showing a sufficient therapeutic effect of the chemotherapy. Background technique [0002] There are various treatment methods for hepatocellular carcinoma, including surgical resection, hepatic artery embolization (hereinafter referred to as "TAE"), percutaneous local therapy (percutaneous ethanol injection therapy, percutaneous radiowave ablation therapy, etc.) etc.), chemotherapy, radiation therapy, liver transplantation, etc. TAE is a surgical treatment method for se...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/404A61P35/00C07D403/06
CPCG01N33/18A61K31/404G01N33/1826G01N33/50G01N2800/52C07D403/06A61P1/16A61P35/00
Inventor 冈俊范
Owner TAIHO PHARMA CO LTD